CD44 targeting is used in the treatment of acute myeloid leukemia (AML) (Jin et al., 2006), CD24 targeting is for the treatment of colon and pancreatic cancer (Sagiv et al., 2008) and CD133 is targeted for the treatment of hepatocellular and gastric cancer (Smith et al., 2008). The gene discussed is PROM1; the disease is acute myeloid leukemia.